Amsacrine Anticancer Drugs Oncology Pharmacology Physiotherapy

Amsacrine (Oncology-3)

In this article we will discuss Amsacrine (Oncology-3)

In this article, we will discuss Amsacrine (Oncology-3). So, let’s get started.

The elimination half-time was increased to 17 h in patients with impaired liver
function, but it was not altered significantly in patients with renal impairment. Urinary excretion of amsacrine over 72 h, typically around 12% of the dose, decreased to only 2% in patients with renal impairment and increased to 20% in patients with hepatic
impairment (Hall et al., 1983). After administration of amsacrine, the total amount of radiolabel excreted in urine was 35% in patients with normal organ function, 49% in patients with liver impairment and 2–16% in patients with renal impairment. Patients with decreased amsacrine clearance rates experienced more toxicity. In two patients from whom biliary outflow was collected, 8% and 36% of the administered radiolabel was recovered within 72 h, < 2% being unchanged amsacrine (Hall et al., 1983).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.